2024
Venous Thromboembolism Prophylaxis in Pregnancy: Why are the U.S. and European Guidelines so Different? Recent Studies and Clinical Insights
Piacquadio M, Paidas M. Venous Thromboembolism Prophylaxis in Pregnancy: Why are the U.S. and European Guidelines so Different? Recent Studies and Clinical Insights. Current Obstetrics And Gynecology Reports 2024, 14: 3. DOI: 10.1007/s13669-024-00407-9.Peer-Reviewed Original ResearchLow-molecular-weight heparinVenous thromboembolism prophylaxisVenous thromboembolismObstetric patientsEuropean guidelinesPostpartum periodHospitalized obstetric patientsMolecular weight heparinMechanical VTE prophylaxisVTE risk stratificationRandomized Controlled StudyObstetric populationPregnant populationRisk stratificationThromboembolism prophylaxisVTE prophylaxisInstitutional protocolMechanical prophylaxisWeight heparinProphylaxisAnticoagulant agentsPregnancyPoor adherenceControlled studiesPatientsScreening and Prophylaxis for Venous Thromboembolism in Pediatric Surgery: A Systematic Review
Kelley-Quon L, Acker S, St Peter S, Goldin A, Yousef Y, Ricca R, Mansfield S, Sulkowski J, Huerta C, Lucas D, Rialon K, Christison-Lagay E, Ham P, Rentea R, Beres A, Kulaylat A, Chang H, Polites S, Diesen D, Gonzalez K, Wakeman D, Baird R. Screening and Prophylaxis for Venous Thromboembolism in Pediatric Surgery: A Systematic Review. Journal Of Pediatric Surgery 2024, 59: 161585. PMID: 38964986, DOI: 10.1016/j.jpedsurg.2024.05.015.Peer-Reviewed Original ResearchIncidence of venous thromboembolismVenous thromboembolismPharmacological prophylaxisSystematic reviewUltrasound screeningEpidemiology of venous thromboembolismAmerican Pediatric Surgical Association OutcomesPreferred Reporting ItemsStudy systematically reviewsLow-molecular-weight heparinRoutine ultrasound screeningCongenital heart diseasePediatric trauma populationPediatric surgical populationBody mass indexPediatric surgical patientsMolecular weight heparinSequential compression devicesInjury Severity ScoreCentral line placementSpinal cord injuryInflammatory bowel diseaseWeb of Science databasesLength of stayReporting ItemsPropensity weighted analysis of chemical venous thromboembolism prophylaxis agents in isolated severe traumatic brain injury: An EAST sponsored multicenter study
Ratnasekera A, Seng S, Kim D, Ji W, Jacovides C, Kaufman E, Sadek H, Perea L, Poloni C, Shnaydman I, Lee A, Sharp V, Miciura A, Trevizo E, Rosenthal M, Lottenberg L, Zhao W, Keininger A, Hunt M, Cull J, Balentine C, Egodage T, Mohamed A, Kincaid M, Doris S, Cotterman R, Seegert S, Jacobson L, Williams J, Moncrief M, Palmer B, Mentzer C, Tackett N, Hranjec T, Dougherty T, Morrissey S, Donatelli-Seyler L, Rushing A, Tatebe L, Nevill T, Aboutanos M, Hamilton D, Redmond D, Cullinane D, Falank C, McMellen M, Duran C, Daniels J, Ballow S, Schuster K, Ferrada P. Propensity weighted analysis of chemical venous thromboembolism prophylaxis agents in isolated severe traumatic brain injury: An EAST sponsored multicenter study. Injury 2024, 55: 111523. PMID: 38614835, DOI: 10.1016/j.injury.2024.111523.Peer-Reviewed Original ResearchConceptsVenous thromboembolism prophylaxis initiationLow-molecular-weight heparinVenous thromboembolism prophylaxisChemical venous thromboembolism prophylaxisVenous thromboembolismIsolated severe traumatic brain injuryUnfractionated heparinSevere traumatic brain injuryNeurosurgical interventionTraumatic brain injuryVTE prophylaxis agentLow-molecular-weight heparin injectionsLow-molecular-weight heparin groupPropensity weighted analysisVenous thromboembolic eventsCox proportional hazards modelsMolecular weight heparinMulti-center analysisYears of ageProportional hazards modelStatistically significant differenceII trauma centerSubcutaneous UH
2023
Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer
Zhang W, Sun R, Hu X, Chen Z, Lai C. Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer. World Journal Of Surgical Oncology 2023, 21: 299. PMID: 37735407, PMCID: PMC10512522, DOI: 10.1186/s12957-023-03183-7.Peer-Reviewed Original ResearchConceptsCaprini risk assessment modelLow-molecular-weight heparinLaparoscopic radical resection of colorectal cancerResection of colorectal cancerRadical resection of colorectal cancerLaparoscopic radical resectionLMWH groupD-dimerDeep vein thrombosisCut-off valueVein thrombosisROC curveColorectal cancerIPC groupClinical data of patientsLow incidence of thrombosisOccurrence of deep vein thrombosisAccurate risk stratificationDecision curve analysisData of patientsColorectal cancer patientsIncidence of thrombosisIncidence of DVTMolecular weight heparinArea under the ROC curve
2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma
Shayeb A, McManus H, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan C, Barata P, Bilen M, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 21: 55-62. PMID: 36411184, DOI: 10.1016/j.clgc.2022.10.013.Peer-Reviewed Original ResearchConceptsLow molecular weight heparinRenal cell carcinomaMajor bleeding eventsBleeding eventsRecurrent VTECell carcinomaDirect oral anticoagulant useAdvanced renal cell carcinomaDifferent anticoagulantsPrimary safety endpointSafety of cabozantinibOral anticoagulant usePrimary efficacy endpointClear cell histologyReal-world cohortRetrospective multicenter studyRisk-benefit discussionsLimited safety dataVenous thromboembolism managementMolecular weight heparinAnticoagulant groupConcurrent anticoagulationDOAC groupThrombosis complicationsEfficacy endpointLow Molecular Weight Heparin, Unfractionated Heparin and Neuraxial Anaesthesia
Combs D, Leffert L. Low Molecular Weight Heparin, Unfractionated Heparin and Neuraxial Anaesthesia. 2022, 329-335. DOI: 10.1007/978-3-030-72487-0_49.Peer-Reviewed Original Research
2021
Use of Pharmacologic Prophylaxis Against Venous Thromboembolism in Hospitalized Injured Children
Mahajerin A, Petty JK, Hanson SJ, Shabanova V, Faustino EVS. Use of Pharmacologic Prophylaxis Against Venous Thromboembolism in Hospitalized Injured Children. Journal Of Pediatric Hematology/Oncology 2021, 44: e349-e357. PMID: 33885041, DOI: 10.1097/mph.0000000000002167.Peer-Reviewed Original ResearchConceptsReceipt of prophylaxisRisk of VTEVenous thromboembolismInjured childrenRisk prediction modelPharmacologic prophylaxisTrauma Quality Improvement ProgramLow molecular weight heparinHospitalized injured patientsPediatric-specific evidencePractice management guidelinesRandomized clinical trialsMolecular weight heparinQuality Improvement ProgramUnfractionated heparinWeight heparinRetrospective studyInjured patientsClinical trialsProphylaxisManagement guidelinesThromboembolismPatientsHigh rateChildrenEvaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
Mesleh Shayeb A, Urman D, Dizman N, Meza L, Sivakumar A, Gan C, Dzimitrowicz H, Zhang T, Barata P, Bilen M, Gao X, Heng D, Pal S, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 291-291. DOI: 10.1200/jco.2021.39.6_suppl.291.Peer-Reviewed Original ResearchLow molecular weight heparinDirect oral anticoagulantsRenal cell carcinomaAdvanced renal cell carcinomaMajor bleeding eventsVenous thromboembolismBleeding eventsMajor bleedingSafety profileDifferent anticoagulantsSimilar bleeding riskRecurrent venous thromboembolismClear cell histologyRetrospective multicenter studyMolecular weight heparinCause of deathFisher's exact testLMWH useRCC outcomeBleeding riskMedian doseOral anticoagulantsPrimary endpointSecondary endpointsVTE events
2020
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke. Stroke 2020, 51: 2724-2732. PMID: 32757753, PMCID: PMC7484360, DOI: 10.1161/strokeaha.120.028867.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaEmbolismFemaleHeart DiseasesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedNeuroimagingRecurrenceRegistriesRetrospective StudiesRisk AssessmentStrokeTreatment OutcomeUnited StatesWarfarinConceptsSymptomatic intracranial hemorrhageRecurrent ischemic eventsLow molecular weight heparinAcute ischemic strokeMolecular weight heparinIschemic eventsIntracranial hemorrhageIschemic strokeAtrial fibrillationAnalysis inclusion criteriaEarly recurrenceWeight heparinInclusion criteriaSeparate Cox regression analysesComprehensive stroke centerLarge prospective studiesOral anticoagulant therapyCox regression analysisCox regression modelAnticoagulation typeDOAC treatmentStroke RegistryAnticoagulant therapyCardioembolic strokeStroke centers
2019
Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey
Pine A, Lee A. Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey. Blood 2019, 134: 2097. DOI: 10.1182/blood-2019-130200.Peer-Reviewed Original ResearchCancer-associated venous thromboembolismDirect oral anticoagulantsUse of DOACsLow molecular weight heparinProvider comfort levelMajority of providersHealth systemWarfarin useOral anticoagulantsClinical trialsUtilization of DOACsYale New Haven Health SystemNational Comprehensive Cancer NetworkDifferent anticoagulantsProspective real-world dataCancer-Associated ThromboembolismUse of apixabanUse of enoxaparinUse of rivaroxabanComprehensive Cancer NetworkRetrospective registry studyCancer care centerMolecular weight heparinMore providersClinical trial resultsPotential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism
Djulbegovic M, Chen K, Sureshanand S, Chaudhry S. Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism. Blood 2019, 134: 3385. DOI: 10.1182/blood-2019-131827.Peer-Reviewed Original ResearchHospital-associated venous thromboembolismPharmacologic VTE prophylaxisVenous thromboembolismRisk-adapted approachMedical inpatientsClinical pharmacy programLower riskMedical overuseRisk of VTELow molecular weight heparinAvoidable harmYale-New Haven HospitalFull-dose anticoagulationGuideline-recommended strategiesAcute medical illnessIncidence of strokeIntensive care unitTime of admissionElectronic health record dataMolecular weight heparinICD-10 codesHealth record dataLower limb paralysisActive cancerDose anticoagulationPhysician Practice Patterns for Performing Thoracentesis in Patients Taking Anticoagulant Medications
DeBiasi EM, Murphy TE, Araujo KLB, Pisani MA, Puchalski JT. Physician Practice Patterns for Performing Thoracentesis in Patients Taking Anticoagulant Medications. Journal Of Bronchology & Interventional Pulmonology 2019, 27: 42-49. PMID: 31436608, PMCID: PMC6923589, DOI: 10.1097/lbr.0000000000000614.Peer-Reviewed Original ResearchConceptsPractice patternsDirect oral anticoagulant useLow molecular weight heparinSafety of thoracentesisHigh bleeding riskOral anticoagulant useDirect oral anticoagulantsMolecular weight heparinAmerican Thoracic SocietyPhysician practice patternsPractices of physiciansAcademic medical centerAntiplatelet medicationsBleeding riskOral anticoagulantsAnticoagulant medicationAnticoagulant useEmail distribution listsProphylactic dosesWeight heparinThoracic SocietyGeneral pulmonologistsMedical CenterInterventional pulmonologistsThoracentesis
2018
Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapyBullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature
Russo A, Curtis S, Balbuena-Merle R, Wadia R, Wong E, Chao HH. Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature. Experimental Hematology & Oncology 2018, 7: 15. PMID: 29989046, PMCID: PMC6035443, DOI: 10.1186/s40164-018-0108-7.BooksLow molecular weight heparinBullous hemorrhagic dermatosisWeight heparinCoagulation testingFull-dose low molecular weight heparinMajority of patientsSmall case seriesMolecular weight heparinDays of administrationSearch of PubMedSite of injectionCase seriesIntracranial hemorrhageOvid EmbaseCase reportElderly menLate diagnosisTherapeutic rangeOvid MEDLINEAnticoagulationSide effectsPatientsTherapeutic interventionsNew casesDifferent anticoagulants
2017
Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies
Quao ZC, Tong M, Bryce E, Guller S, Chamley LW, Abrahams VM. Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. American Journal Of Reproductive Immunology 2017, 79 PMID: 29135051, PMCID: PMC5728699, DOI: 10.1111/aji.12785.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntiphospholipidAntiphospholipid SyndromeAspirinbeta 2-Glycoprotein ICells, CulturedChemokinesDisease ProgressionDrug Therapy, CombinationEndometriumEndothelial CellsFemaleHeparin, Low-Molecular-WeightHumansMembrane ProteinsNeovascularization, PhysiologicPregnancyPregnancy ComplicationsTrophoblastsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1ConceptsLow molecular weight heparinHuman endometrial endothelial cellsMolecular weight heparinUterine endotheliumAntiphospholipid antibodiesWeight heparinInfluence of LMWHLow dose low molecular weight heparinAnti-angiogenic sFlt-1Chemokine MCP-1Endometrial endothelial cellsEffects of aPLSFlt-1 releaseAngiogenic factor secretionObstetric APSPregnancy complicationsControl IgGChemokine profilesEndothelium dysfunctionChemokine secretionPro-angiogenic VEGFCombination therapySFlt-1Impaired placentationMCP-1
2015
Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study
Shatzel J, Dulai P, Harbin D, Cheung H, Reid T, Kim J, James S, Khine H, Batman S, Whyman J, Dickson R, Ornstein D. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study. Journal Of Thrombosis And Haemostasis 2015, 13: 1245-1253. PMID: 25955079, PMCID: PMC6658183, DOI: 10.1111/jth.13000.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedAnticoagulantsDrug Administration ScheduleFemaleGastrointestinal HemorrhageHeparin, Low-Molecular-WeightHospitalizationHumansLength of StayLiver CirrhosisMaleMiddle AgedNew HampshireOdds RatioRetrospective StudiesRisk FactorsTertiary Care CentersTime FactorsTreatment OutcomeVenous ThromboembolismConceptsLow molecular weight heparinHospital bleeding eventsRetrospective cohort studyMolecular weight heparinVTE prophylaxisVenous thromboembolismBleeding eventsPharmacological thromboprophylaxisCirrhotic patientsCohort studyUnfractionated heparinWeight heparinSingle-center retrospective cohort studyEnd-stage liver disease (MELD) scoreAcademic tertiary care referral centerRate of VTETertiary care referral centerRisk of VTEGastrointestinal bleeding eventsHospitalized cirrhotic patientsNew VTE eventsPharmacological VTE prophylaxisLiver Disease scoreHospital bleedingVTE eventsThromboprophylaxis in critically ill children in Spain and Portugal
Núñez A, Fonte M, Faustino E, del estudio multicéntrico internacional PROTRACT E. Thromboprophylaxis in critically ill children in Spain and Portugal. Anales De Pediatría (English Edition) 2015, 82: 144-151. DOI: 10.1016/j.anpede.2014.05.002.Peer-Reviewed Original ResearchDeep venous thrombosisLow molecular weight heparinMolecular weight heparinIll childrenInternational PICUsWeight heparinRisk factorsEffectiveness of thromboprophylaxisUse of thromboprophylaxisPercentage of patientsFemoral vein catheterPharmacological thromboprophylaxisThromboprophylaxis useMechanical thromboprophylaxisCentral cathetersVenous thrombosisVein catheterFemoral veinResultsA totalThromboprophylaxisMethodsSecondary analysisPrior historyPatientsPICUsCranial trauma
2014
Patency Rates of Portal Vein/Superior Mesenteric Vein Reconstruction After Pancreatectomy for Pancreatic Cancer
Krepline A, Christians K, Duelge K, Mahmoud A, Ritch P, George B, Erickson B, Foley W, Quebbeman E, Turaga K, Johnston F, Gamblin T, Evans D, Tsai S. Patency Rates of Portal Vein/Superior Mesenteric Vein Reconstruction After Pancreatectomy for Pancreatic Cancer. Journal Of Gastrointestinal Surgery 2014, 18: 2016-2025. PMID: 25227638, DOI: 10.1007/s11605-014-2635-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMesenteric VeinsMiddle AgedPancreatectomyPancreatic NeoplasmsPlastic Surgery ProceduresPortal VeinPostoperative ComplicationsRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeVascular PatencyVascular Surgical ProceduresConceptsVenous reconstructionPancreatic cancerPrimary anastomosisSegmental resectionFollow-upSuperior mesenteric-portal vein confluenceSurgery to last follow-upPatency ratesMedian time to detectionMedian Follow-UpLast follow-upType of reconstructionMolecular weight heparinSaphenous vein patchLong-term patencyTangential resectionPancreatic resectionVein preservationVein reconstructionPrimary repairVein divisionTime to detectionPharmacological therapyVein interpositionWeight heparin
2009
National Healthcare Utilization Trends for Deep Vein Thrombosis in the United States.
Viswanathan P, Goswami U, Krishnamurti L. National Healthcare Utilization Trends for Deep Vein Thrombosis in the United States. Blood 2009, 114: 3183. DOI: 10.1182/blood.v114.22.3183.3183.Peer-Reviewed Original ResearchNationwide Inpatient SampleLow molecular weight heparinPostoperative pulmonary embolismDeep vein thrombosisHealth care utilizationMolecular weight heparinPrimary diagnosisSecondary diagnosisPulmonary embolismVein thrombosisAnnual incidenceCare utilizationWeight heparinDischarge diagnosisHospital utilizationAge 18ICD-9-CM diagnosisLarge-scale prospective studiesCommon primary diagnosisPatients age 18Primary discharge diagnosisPulmonary heart diseaseAcute care hospitalsVariety of diagnosesHealthcare utilization trends
2008
Early Postoperative Hemorrhage After Open and Laparoscopic Roux-En-Y Gastric Bypass
Bakhos C, Alkhoury F, Kyriakides T, Reinhold R, Nadzam G. Early Postoperative Hemorrhage After Open and Laparoscopic Roux-En-Y Gastric Bypass. Obesity Surgery 2008, 19: 153-157. PMID: 18629595, DOI: 10.1007/s11695-008-9580-1.Peer-Reviewed Original ResearchConceptsLow molecular weight heparinPostoperative hemorrhageGastric bypassHospital staySurgical reexplorationLaparoscopic Roux-EnPostoperative blood transfusionResultsThirty-three patientsLonger hospital stayY Gastric BypassIncidence of hemorrhageMolecular weight heparinTechnical risk factorsLaparoscopic groupPreoperative administrationBleeding groupOpen RouxPostoperative administrationRoux-enEarly hemorrhageInfrequent complicationAverage BMIBlood transfusionLaparoscopic approachClinical presentation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply